Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted Analysis

NCT07549269 | Completed

• 1 other identifier: Paclitax
• Study Type: observational
• Target: 387
• Locations: 1 country
• Sites: 3

Brief Summary

Taxane-based agents are widely used in the treatment of esophageal squamous cell carcinoma (ESCC). Among these, nab-paclitaxel (albumin-bound paclitaxel) and paclitaxel are the most commonly used. However, there is currently no definitive evidence comparing the efficacy of these two agents in the context of neoadjuvant therapy for ESCC.

Conditions

Esophageal Cancer

Keywords

ESCC; Neoadjuvant therapy; Nab-Paclitaxel, Paclitaxel

Outcome Measures

Primary Outcomes (3)

• PCR

  Pathological Complete Response

  Within 4 weeks after surgery

• DFS

  disease-free survival

  From the date of esophagectomy until the date of first documented disease recurrence, disease progression, or death from any cause, whichever came first, assessed up to 60 months.

• OS

  overall survival

  From the date of initial diagnosis of esophageal squamous cell carcinoma until the date of death from any cause or the date of last follow-up, whichever came first, assessed up to 60 months.

Study Arms (2)

Nab-P cohort

Drug: The cohort included 161 patients treated with solvent-based paclitaxel and 226 treated with nanoparticle albumin-bound paclitaxel.

PTX cohort

Drug: The cohort included 161 patients treated with solvent-based paclitaxel and 226 treated with nanoparticle albumin-bound paclitaxel.

Interventions

The cohort included 161 patients treated with solvent-based paclitaxel and 226 treated with nanoparticle albumin-bound paclitaxel. DRUG

Nab-P group Intervention Type: Drug Intervention Name: Nab-paclitaxel Description: Patients had received nab-paclitaxel-based chemotherapy as part of neoadjuvant immunochemotherapy before esophagectomy. Treatment was administered as part of routine clinical care and was not assigned by the investigators for this retrospective observational study. PTX group Intervention Type: Drug Intervention Name: Paclitaxel Description: Patients had received paclitaxel-based chemotherapy as part of neoadjuvant immunochemotherapy before esophagectomy. Treatment was administered as part of routine clinical care and was not assigned by the investigators for this retrospective observational study.

Nab-P cohort; PTX cohort

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

This retrospective study included 1877 ESCC patients who underwent esophagectomy at West China Hospital of Sichuan University and two other centers between June 2019 and December 2024. After screening, 387 eligible patients were included.

You may qualify if:

• Histologically confirmed diagnosis of esophageal squamous cell carcinoma (ESCC).
• Patients with resectable or potentially resectable disease based on baseline clinical assessment.

You may not qualify if:

• Presence of any untreated malignancy within the past five years, except fully treated cervical carcinoma in situ or basal cell carcinoma/squamous cell skin cancer.
• Receipt of other neoadjuvant treatments, including chemotherapy, chemoradiotherapy, or chemoradiotherapy combined with immunotherapy.
• Incomplete medical records.
• Refusal to participate in follow-up.

Sponsors & Collaborators

• Sichuan University: lead

Study Sites (3)

West China Hospital

Chengdu, Sichuan, China

Location

Mianzhu People's Hospital（West China Mianzhu Hospital, Sichuan University)

Mianzhu, Sichuan, 861916, China

Location

Suining Central Hospital

Suining, Sichuan, China

Location

MeSH Terms

Conditions

Esophageal Neoplasms

Interventions

Taxes

Condition Hierarchy (Ancestors)

Gastrointestinal Neoplasms; Digestive System Neoplasms; Neoplasms by Site; Neoplasms; Head and Neck Neoplasms; Digestive System Diseases; Esophageal Diseases; Gastrointestinal Diseases

Intervention Hierarchy (Ancestors)

Economics; Health Care Economics and Organizations

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: professor

Study Record Dates

• First Submitted: April 9, 2026
• First Posted: April 24, 2026
• Study Start: April 1, 2026
• Primary Completion: July 1, 2026
• Study Completion: August 1, 2026
• Last Updated: August 24, 2026

Record last verified: 2026-08

Locations

CN (3)